Get the Stockscreener App
31.45
0.66%
-0.21
Pre-market:
31.00
-0.45
-1.43%
Ultragenyx Pharmaceutical Inc stock is traded at $31.45, with a volume of 1.57M.
It is down -0.66% in the last 24 hours and up +0.51% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
See More
Previous Close:
$31.66
Open:
$31.81
24h Volume:
1.57M
Relative Volume:
0.75
Market Cap:
$3.03B
Revenue:
$522.75M
Net Income/Loss:
$-558.99M
P/E Ratio:
-4.8609
EPS:
-6.47
Net Cash Flow:
$-439.53M
1W Performance:
+0.77%
1M Performance:
+0.51%
6M Performance:
-5.16%
1Y Performance:
-41.62%
1-Day Range:
$30.93
$31.84
1-Week Range:
$29.57
$32.10
52-Week Range:
$25.81
$57.99
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
31.45 | 3.05B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | William Blair | Outperform |
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Will Ultragenyx Pharmaceutical Inc. stock benefit from upcoming earnings reports2025 Big Picture & Community Trade Idea Sharing Platform - newser.com
Sentiment analysis tools applied to Ultragenyx Pharmaceutical Inc.Market Sentiment Review & Safe Capital Growth Stock Tips - newser.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Can Ultragenyx Pharmaceutical Inc. (UP0) stock hold up in economic slowdownJuly 2025 WrapUp & AI Forecast for Swing Trade Picks - newser.com
Ultragenyx Pharmaceutical Inc. stock prediction for this weekWeekly Trade Review & Reliable Trade Execution Plans - newser.com
What sentiment indicators say about Ultragenyx Pharmaceutical Inc. stockCPI Data & Capital Protection Trade Alerts - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE) - MarketBeat
What moving averages say about Ultragenyx Pharmaceutical Inc.2025 Technical Overview & Free Weekly Watchlist of Top Performers - newser.com
Does Ultragenyx Pharmaceutical Inc. show high probability of reboundWeekly Risk Report & Advanced Swing Trade Entry Plans - newser.com
Predicting Ultragenyx Pharmaceutical Inc. trend using moving averagesJuly 2025 Chart Watch & Safe Entry Point Identification - newser.com
What drives Ultragenyx Pharmaceutical Inc stock priceTechnical Analysis Insights & Hidden Gems with Outstanding Profit Margins - earlytimes.in
Wealth Enhancement Advisory Services LLC Takes $353,000 Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE) - Yahoo Finance
Pattern recognition hints at Ultragenyx Pharmaceutical Inc. upsideWeekly Volume Report & High Conviction Buy Zone Picks - newser.com
Why Ultragenyx Pharmaceutical Inc. (UP0) stock signals breakout potentialJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - newser.com
How to read the order book for Ultragenyx Pharmaceutical Inc.Share Buyback & Free Daily Entry Point Trade Alerts - newser.com
Ultragenyx Pharmaceutical Inc. stock trend outlook and recovery path2025 Key Lessons & Weekly High Potential Stock Alerts - newser.com
Will Ultragenyx Pharmaceutical Inc. (UP0) stock outperform energy sector in 2025Watch List & High Accuracy Swing Entry Alerts - newser.com
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $80 - 富途牛牛
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
62,232 Options & 34,564 RSUs: Ultragenyx Grants Inducement Award to New Hire, Grant Date Sep 30, 2025 - Stock Titan
Ultragenyx Pharmaceutical (RARE): Valuation Perspectives Following Regulatory Milestones and Pipeline Progress - Yahoo Finance
Ultragenyx Pharmaceutical (RARE): Evaluating Valuation After Strategic Leadership Transition with Eric Olson - Sahm
Using RSI to spot recovery in Ultragenyx Pharmaceutical Inc.Weekly Investment Recap & Smart Money Movement Tracker - newser.com
Tools to monitor Ultragenyx Pharmaceutical Inc. recovery probabilityAnalyst Downgrade & Precise Swing Trade Entry Alerts - newser.com
How to monitor Ultragenyx Pharmaceutical Inc. with trend dashboards2025 Short Interest & High Return Trade Guides - newser.com
How Might Ultragenyx (RARE) Leverage Dealmaking Expertise to Shape Its Long-Term Growth Strategy? - Yahoo Finance
Ultragenyx (RARE) Poised for Positive Developments, Says JPMorga - GuruFocus
Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline - Insider Monkey
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical - openPR.com
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical Progress by 8+ Global Leaders – DelveInsight | Featuring Ultragenyx Pharmaceutical Inc, JCR Pharmaceuticals Co., Ltd., GC Biopharma Corp, D - The Globe and Mail
Ultragenyx Pharmaceutical Hits Day High with Strong 8.12% Intraday Surge - Markets Mojo
Ultragenyx Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
United States Osteogenesis Imperfecta Treatment Market - openPR.com
Ultragenyx appoints Eric Olson as chief business officer By Investing.com - Investing.com Nigeria
Revolution Medicines hires Mirati, ALX vet Sandler - biocentury.com
7 Most Promising Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Ultragenyx appoints Eric Olson as chief business officer and executive vice president - MarketScreener
Ultragenyx appoints Eric Olson as chief business officer - Investing.com India
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President - GlobeNewswire
Ultragenyx appoints Eric Olson Chief Business Officer - TipRanks
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):